GlassScriptPhysician profile
Aliza Lifshitz
NPI 1477533875
$15,755.96
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $24.24 · 2021: $15K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15,000.00 | 2021 | |
| Amgen INC. | $214.23 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $84.94 | 2019-2020 | |
| Daiichi Sankyo INC. | $77.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $58.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $55.25 | 2019 | |
| Glaxosmithkline, LLC. | $31.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $31.11 | 2019 | |
| La Jolla Pharmaceutical Company | $26.02 | 2019 | |
| Abbvie INC. | $22.51 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.99 | 2019 | |
| Amarin Pharma, INC. | $20.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.52 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.03 | 2019 | |
| Shire North American Group INC | $18.64 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $18.44 | 2019 | |
| Lilly USA, LLC | $14.80 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.29 | 2019 | |
| Radius Health, INC. | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliza Lifshitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.